

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF  
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): July 16, 2015

**DELMAR PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

**Nevada**

**000-54801**

**99-0360497**

(State or Other Jurisdiction of  
Incorporation)

(Commission File Number)

(I.R.S. Employer Identification Number)

Suite 720-999 West Broadway  
Vancouver, British Columbia  
Canada V5Z 1K5  
(Address of principal executive offices) (zip code)

(604) 629-5989  
(Registrant's telephone number, including area code)

Copies to:  
Gregory Sichenzia, Esq.  
Jeff Cahlon, Esq.  
Sichenzia Ross Friedman Ference LLP  
61 Broadway  
New York, New York 10006  
Phone: (212) 930-9700  
Fax: (212) 930-9725

(Former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01 Other Events.**

Between July 16, 2015 and July 26, 2015, DelMar Pharmaceuticals, Inc. (the “Company”) entered into subscription agreements for the sale of 3.35 million shares of common stock and 3.35 million common stock purchase warrants for an aggregate purchase price of \$2 million (including subscription agreements with officers and directors of the Company for an aggregate purchase price of \$157,000), pursuant to the Company’s public offering on Form S-1. The warrants have a term of five years and an exercise price of \$0.75 per share.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

<b>Exhibit Number</b>	<b>Description</b>
99.1	Form of Subscription Agreement (United States) (incorporated by reference to Form S-1/A filed with the SEC on July 9, 2015)
99.2	Form of Subscription Agreement (Canada) (incorporated by reference to Form S-1/A filed with the SEC on July 9, 2015)
99.3	Form of Warrant (incorporated by reference to Form S-1/A filed with the SEC on July 9, 2015)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**DELMAR PHARMACEUTICALS, INC.**

Dated: July 27, 2015

By: /s/ Jeffrey Bacha  
Name: Jeffrey Bacha  
Title: Chief Executive Officer

---